Discussing β-lactamase/β-lactamase inhibitors (AAC ed.)
Editors in Conversation
English - February 10, 2023 11:00 - 51 minutes - 35.2 MB - ★★★★ - 10 ratingsLife Sciences Science Health & Fitness Medicine asm for fox interviews jeff magazine microbe microbiology news science Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Molecular Testing for Periprosthetic Joint Infections (JCM ed.)
Next Episode: Avoiding HIV False Positives (JCM ed.)
Novel β-lactamase/β-lactamase inhibitors have become critical drugs to combat the most resistant Gram-negative infections. A series of new compounds with even more broad and potent activity are in the horizon to add to the therapeutic armamentarium. Today, we will discuss these drugs with experts in the field.
Topics discussed: BL/BLI combinations that are currently available in clinical practice. Future perspectives of BL/BLI armamentarium. Resistance developing for this class of antibiotics. Guests: Robert Bonomo. Professor, Department of Medicine, Pharmacology and Molecular Biology and Microbiology, Case Western Reserve University, Director of VA CARES Center, Cleveland, OH Patricia A. Bradford Antimicrobial Development Specialists LLC, Nyack, New York, USAThis episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at aac.asm.org. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/membership to sign up.
Visit journals.asm.org/journal/aac to browse issues and/or submit a manuscript.